A study in the New England Journal of Medicine by Hayek Salim S. et al published on Jan. 30, shows that high soluble urokinase receptor (suPAR) levels were associated with incident acute kidney injury in several patient cohorts. 1

The analysis comprises an independent review of the Company, its products, markets and competitors as well as a financial scenario that constitutes the basis of an estimated justified market capitalization of ViroGates.

ViroGates has made a distribution agreement with Interlux Group based in Lithuania, that grants Interlux the rights to distribute ViroGates’ product range suPARnostic® in the Baltic region.

ViroGates announces that it has completed the development and regulatory approval (CE-IVD) of its suPARnostic® TurbiLatex product for the ADVIA® Chemistry XPT System from Siemens Healthineers.

suPARnostic® will now be available for clinical decision making at Sygehus Lillebaelts two hospitals in Kolding and Vejle, Denmark. Both hospitals use the cobas system from Roche Diagnostics, an instrument line that was validated by ViroGates for use of the suPARnostic® TurbiLatex test earlier this year.

Read the Journal "suPAR News" No. 2, 2019 - with lots of interesting articles and interviews from around Europe!